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IMPACT OF DEXMEDETOMIDINE ON OPIOID AND
BENZODIAZEPINE DOSING REQUIREMENTS IN CHILDREN
Amy E. Helvie*, PharmD, Chad A. Knoderer, PharmD, Iftekhar D. Kalsekar, PhD,
Brandon T. Kibby, DO, Michael S. Mazurek, MD
*Department of Pharmacy, Riley Hospital for Children, Indianapolis IN.
RESULTS

Dexmedetomidine
(n = 36)

To determine the difference in opioid and benzodiazepine dosing
requirements in children treated with and without dexmedetomidine after
cardiac surgery.

Study Design
IRB approved retrospective cohort study

Opioid and Midazolam Dosing Requirements
 Total daily opioid dosing requirements were reduced 37% in the dexmedetomidine
verus the comparison group.
 Patients in the dexmedetomidine group had higher midazolam dosing requirements.

Mean daily dosing requirements

Baseline Demographics

OBJECTIVES

METHODS

RESULTS

Thirty six patients in each group were included.
Baseline Demographics
•No difference between groups

No
Dexmedetomidine
(n = 36)

6

p

Age*
(months)

50.9 (0.85 – 207.4)

44.9 (0.13 – 233)

0.707

Weight*
(kg)

18.5 (3.2 – 104)

16.4 (2 – 99)

0.695

mg/kg/day

BACKGROUND
 Dexmedetomidine is a potent and selective alpha2-adrenergic agonist which
has sedative, analgesic, and anxiolytic effects.
 In adults, dexmedetomidine has been shown to decrease opioid dosing
requirements when utilized for pain and sedation management.
 We hypothesized that similar to adult data, the addition of dexmedetomidine to
standard pain and sedation management protocols may reduce the overall opioid
and benzodiazepine dosing requirements in children after cardiac surgery.
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Patient Population
 Patients included were pediatric cardiovascular surgery patients who were admitted
to the intensive care unit post-operatively.
 Exclusion criteria:
Patients greater than 18 years
Cardiovascular surgery patients whose operative procedure was not performed
for repair or palliation of a congenital heart defect
Dexmedetomidine patients who did not have dexmedetomidine initiated within 24
hours of surgery.
Pain and Sedation Management
 Standard pain management and sedation protocol managed by pediatric
anesthesiologist in all patients.
 Therapeutic options and dosing were dependent on patient’s airway status.
Mechanically ventilated
Continuous fentanyl infusion
As needed (PRN) IV morphine
PRN IV midazolam
+/- dexmedetomidine
Spontaneously breathing
PRN IV morphine
PRN IV midazolam
+/- dexmedetomidine

Male

21 (58%)

20 (56%)

0.812

Bypass

35 (97%)

34 (94%)

0.555

Intubated

26 (72%)

20 (56%)

0.141

RACHS-1,
n (%)
1
2
3
4
5
6

4 (11%)
9 (25%)
22 (61%)
1 (3%)
0
0

3 (8%)
10 (28%)
21 (58%)
2 (6%)
0
0

1.000
0.789
0.810
1.000
0
0

Dexmedetomidine

Number of doses

Data Source
 Computer generated lists were used to randomly select both case (DEX) and
comparison (COMP) subjects.
 Dosing information was collected via medication administration records for the
duration of anesthesiologist management.
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p = 0.071

No Dexmedetomidine

Mean daily PRN doses
7.3 6.9

6

3.6
4

2.2

2
0
Opiod

Midazolam
p = 0.21
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Continuous Infusions
Fentanyl
Administered to 18 (50%) in the DEX group and 14 (38%) in the COMP group
DEX group required fewer days of therapy 4.8 vs. 8.9 (p = 0.064)
Midazolam
Not utilized in any patient
Dexmedetomidine
Mean initial infusion: 0.34 ± 0.1 mcg/kg/hr
Maximum infusion: 0.44 ± 0.17 mcg/kg/hr
Bolus doses administered to 8 patients (22%)
Average length of infusion: 2.4 ± 1.9 days

Data Analysis
 Total cumulative doses of fentanyl, morphine, and midazolam were determined.
 For equal comparison, opioid dosing was standardized by using equipotent
morphine doses.
.

Dexmedetomidine

No Dexmedetomidine

DISCUSSION
When compared to a historical control population, dexmedetomidine administration
to children within 24 hours after surgery for congenital heart disease, was associated
with a 37% reduction in total daily opioid dosing requirement, although not
statistically significant.
Decreased opioid use may also result in decreased PICU days and
decreased incidences of opioid withdrawal, both of which impact overall
length of stay and associated healthcare costs.
Trending towards statistical significance, a reduction in continuous fentanyl
infusion requirements was also observed.
In our study, cumulative midazolam dosing requirements were higher in patients
who received dexmedetomidine, although not statistically significant.
This could be explained by limited upward dexmedetomidine dose titration
and may signify that the dexmedetomidine doses were not optimized to
achieve desired sedation outcomes.

